Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing

The latest update on Pacira BioSciences lifts the modelled fair value from US$30.00 to about US$33.57 per share, a mid single digit change that reframes where some analysts see the stock settling. With coverage now centered on the agreed US$36.50 per share cash acquisition by Viatris and the question of any remaining upside to that deal price, this new target range helps anchor how research desks are talking about potential outcomes. As you read on, you will see how to track this evolving...